+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug Formulation Market - Global Forecast to 2030- Product Image
Drug Formulation Market - Global Forecast to 2030- Product Image
Sale

Drug Formulation Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967541
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drug Formulation Market grew from USD 2.55 trillion in 2024 to USD 2.70 trillion in 2025. It is expected to continue growing at a CAGR of 5.76%, reaching USD 3.57 trillion by 2030.

The field of drug formulation has undergone a dramatic metamorphosis over the past decade, propelled by advances in biotechnology, materials science, and digital health. Today’s stakeholders-from researchers in academic labs to decision-makers in global pharmaceutical firms-face a landscape marked by complex regulatory requirements, diverse patient needs, and a renewed focus on sustainability. As the interplay between novel molecules and sophisticated delivery platforms intensifies, the industry must navigate uncertainties posed by shifting trade policies, emerging regional markets, and evolving competitive dynamics. This executive summary distills critical insights across segmentation, regional trends, company strategies, and actionable recommendations, offering a coherent framework for understanding how tomorrow’s therapeutics will be designed, manufactured, and delivered.

Transformative Shifts in Drug Formulation and Delivery

The past several years have witnessed seismic shifts in how drugs are formulated and administered. Personalized medicine has challenged conventional one-size-fits-all approaches, while breakthroughs in nanotechnology, molecular engineering, and green chemistry have rewritten the rules for stability, bioavailability, and patient compliance. Digital tools and artificial intelligence now optimize excipient selection, predictive modeling and real-time monitoring have streamlined process development, and regulatory agencies have embraced adaptive pathways that reward innovation. Concurrently, patient expectations have risen: they demand minimally invasive delivery, rapid onset of action, and formulations that integrate seamlessly with wearable sensors or home-use devices. As a result, the industry is transitioning from simple dosage forms to multifunctional platforms capable of targeting specific tissues, modulating release kinetics, and adjusting to dynamic physiological conditions.

Cumulative Impact of United States Tariffs in 2025

In 2025, the United States imposed additional tariffs on critical active pharmaceutical ingredients (APIs), excipients, and specialized delivery components, reshaping cost structures across the supply chain. Manufacturers reliant on overseas sources for high-purity lipids, polymers, or biologic starting materials have faced price inflation, compelling near-term adjustments in sourcing strategies. At the same time, these tariffs have accelerated investments in domestic production-particularly in bioprocessing and green synthesis-by magnifying the value of localized manufacturing. The combined effect has been twofold: more resilient supply networks that can withstand trade disruptions, and a renewed urgency to optimize formulation technologies to offset raw-material costs. Although this shift poses short-term margin pressure, it ultimately incentivizes streamlined operations, enhanced vertical integration, and stronger collaborations between drug developers and CMOs within U.S. borders.

Key Segmentation Insights Driving Formulation Strategies

A nuanced view of market segmentation underscores how formulation strategies must adapt to multiple axes of differentiation. Within the drug‐type dimension, formulators balance the distinct demands of biologics components-ranging from blood products to cell therapy and vaccines-with the stability challenges posed by synthetic small molecules and the potency considerations inherent in high-potency therapeutics and orphan drugs. Delivery-method innovation similarly spans inhalation platforms such as pressurized inhalers, nasal sprays and nebulizer systems, alongside injectable formats that include pre-filled syringes and multi-dose vials, all the way through oral dosage in capsules, powders, and tablets, and topical applications like creams, gels, and transdermal patches. Therapeutic area priorities further refine these choices, with cardiovascular treatments tailored for arrhythmia, heart failure, and hypertension; anti-infectives optimized against bacterial, parasitic, and viral threats; neurology pipelines directed at Alzheimer’s, multiple sclerosis, and Parkinson’s disease; and oncology regimens focused on both hematological malignancies and solid tumors. Formulation technology itself is a critical lever: controlled-release platforms can be tuned to extended or sustained profiles, molecular engineering supports monoclonal antibodies and peptide mimetics, and nanotechnology enables nanoemulsions or nanoparticle carriers that enhance targeted delivery. Production technology choices between bioprocessing techniques-such as chromatography and fermentation-and chemical synthesis approaches like catalysis and solid-state chemistry shape both efficiency and scalability. At the point of care, clinics, home infusion providers and remote-monitoring services, and hospitals-whether inpatient or outpatient-dictate packaging formats, device compatibility, and stability requirements. Finally, market trends around 3D printed drugs with complex structural geometries and rapid dissolution capabilities, biosimilars (interchangeable and non-interchangeable), green chemistry innovations using biodegradable polymers and microalgal derivatives, and personalized medicine based on genomic and proteomic data are converging to redefine the very essence of formulation strategy.

Regional Dynamics Shaping Market Opportunities

Regional dynamics underscore distinct opportunities and challenges across the Americas, Europe, Middle East & Africa (EMEA), and Asia-Pacific markets. North America remains a leader in advanced biologic formulations and digital integration, supported by robust regulatory frameworks and significant R&D budgets. In Latin America, cost-effective small-molecule platforms and biosimilar development are gaining momentum as local manufacturers capitalize on regional partnerships and tailored delivery models. Across EMEA, stringent sustainability mandates and emerging harmonized regulations drive investment in green chemistry and nanotechnology, while the Middle East accelerates facility expansion to serve both local and export demand. In the Asia-Pacific, rapid growth in personalized medicine and 3D printed dosage forms complements expanding contract manufacturing capacity in China, India, and Southeast Asia, where competitive labor costs and government incentives underpin technology transfer and capacity building. These regional nuances require companies to calibrate formulation approaches, adapt packaging and device standards, and align with local reimbursement structures to maximize market penetration.

Profiles of Leading Industry Players

Leading players are capitalizing on formulation innovations, supply-chain resilience and targeted M&A to secure competitive advantage. 3M Company continues to pioneer advanced polymeric excipients and nanostructured carriers, while AbbVie Inc. leverages its expertise in monoclonal antibodies to optimize controlled-release injectable platforms. Amgen, Inc. and AstraZeneca plc. have both expanded bioprocessing footprints, integrating fermentation and chromatography workflows to reduce reliance on imported raw materials. Bayer AG and Boehringer Ingelheim International GmbH focus on green chemistry initiatives, deploying biodegradable polymers and microalgal derivatives to meet tightening environmental standards. Boston Scientific Corporation and Catalent, Inc. drive turnkey drug-device combination products, emphasizing patient-centric design in pre-filled syringes and inhalation systems. Eli Lilly and Company has advanced peptide mimetic formulations, while F. Hoffmann-La Roche AG invests heavily in molecular engineering for next-generation biologics. Gerresheimer AG and Gilead Sciences, Inc. enhance containment systems for high-potency molecules, and GlaxoSmithKline plc. pushes into personalized medicine through genomics-driven dosage optimization. Glenmark Pharmaceuticals Limited and Halozyme Therapeutics, Inc. collaborate on enzyme-enabled subcutaneous formulations, while Johnson & Johnson Services, Inc. and Marksans Pharma Ltd. expand into biosimilars. Medicef Pharma and Merck & Co., Inc. integrate AI-powered predictive analytics for excipient selection, and Novartis AG pilots 3D printed oral dosage forms. Pfizer Inc. and Sanofi SA both champion ocular and inhalation drug delivery, and Teva Pharmaceuticals Industries Ltd. deploys solid-state chemistry to scale generic small-molecule APIs. The Bristol-Myers Squibb Company emphasizes strategic alliances to accelerate cell therapy formulations, underscoring the industry’s push toward collaborative innovation.

Actionable Recommendations for Industry Leaders

To thrive in this intricate landscape, leaders should:
  1. Accelerate adoption of advanced formulation technologies by investing in pilot lines for nanocarriers, molecular engineering and 3D printing to enhance product differentiation and reduce time-to-clinic.
  2. Strengthen supply-chain resilience through dual sourcing of critical raw materials, onshoring of key bioprocessing steps and development of strategic partnerships with regional CMOs to mitigate tariff-driven cost inflation.
  3. Pursue collaborative ecosystems that bring together academia, contract developers, device manufacturers and payers to co-develop integrated solutions-particularly for personalized and high-potency therapeutics.
  4. Align sustainability goals with formulation strategy by adopting green chemistry principles, recyclable packaging and energy-efficient manufacturing processes to meet evolving regulatory and corporate responsibility mandates.
  5. Tailor market entry plans to regional regulatory frameworks and reimbursement models, ensuring that formulations meet local device standards, cold-chain infrastructure capabilities and patient compliance requirements.

Conclusion

Innovation in drug formulation stands at the nexus of patient-centric care, operational efficiency and environmental stewardship. By understanding the forces reshaping segmentation, tariffs, regional dynamics and competitive strategies, pharmaceutical and biotech organizations can make informed decisions that balance risk and opportunity. Embracing advanced delivery platforms, fortifying supply chains against policy fluctuations, and collaborating across the ecosystem will unlock novel therapeutics that improve outcomes while maintaining commercial viability. As the pace of technological change accelerates, the companies that integrate these insights into their roadmaps will emerge as industry leaders in the next generation of drug formulation.

Market Segmentation & Coverage

This research report categorizes the Drug Formulation Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics
    • Blood Products
    • Cell Therapy
    • Vaccines
  • Small Molecule
    • Biopharmaceutical
    • Synthetic
  • Specialty Drugs
    • High-Potency Therapeutics
    • Orphan Drugs
  • Inhalation
    • Inhaler
    • Nasal Spray
    • Nebulizer
  • Injectable
    • Pre-Filled Syringes
    • Vials
  • Oral
    • Capsule
    • Powder
    • Tablet
  • Topical
    • Cream
    • Gel
    • Patch
  • Cardiovascular
    • Arrhythmia
    • Heart Failure
    • Hypertension
  • Infectious Diseases
    • Bacterial Infections
    • Parasitic Infections
    • Viral Infections
  • Neurology
    • Alzheimer's Disease
    • Multiple Sclerosis
    • Parkinson's Disease
  • Oncology
    • Hematological Malignancies
    • Solid Tumors
  • Controlled Release
    • Extended Release
    • Sustained Release
  • Molecular Engineering
    • Monoclonal Antibodies
    • Peptide Mimetic
  • Nanotechnology
    • Nanoemulsions
    • Nanoparticles
  • Bioprocessing
    • Chromatography
    • Fermentation
  • Chemical Synthesis
    • Catalysis
    • Solid State Chemistry
  • Clinics
    • Family Clinics
    • Specialty Clinics
  • Home Care Settings
    • Home Infusion
    • Remote Monitoring
  • Hospitals
    • In-Patient
    • Out-Patient
  • 3D Printed Drugs
    • Complex Structures
    • Rapid Dissolution
  • Biosimilars
    • Interchangeable
    • Non-Interchangeable
  • Green Chemistry
    • Biodegradable Polymers
    • Microalgal Derivatives
  • Personalized Medicine
    • Genomics
    • Proteomics

This research report categorizes the Drug Formulation Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Drug Formulation Market to delves into recent significant developments and analyze trends in each of the following companies:

  • 3M Company
  • AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca plc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Catalent, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gerresheimer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Marksans Pharma Ltd.
  • Medicef Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd.
  • The Bristol-Myers Squibb Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drug Formulation Market, by Drug Type
8.1. Introduction
8.2. Biologics
8.2.1. Blood Products
8.2.2. Cell Therapy
8.2.3. Vaccines
8.3. Small Molecule
8.3.1. Biopharmaceutical
8.3.2. Synthetic
8.4. Specialty Drugs
8.4.1. High-Potency Therapeutics
8.4.2. Orphan Drugs
9. Drug Formulation Market, by Delivery Method
9.1. Introduction
9.2. Inhalation
9.2.1. Inhaler
9.2.2. Nasal Spray
9.2.3. Nebulizer
9.3. Injectable
9.3.1. Pre-Filled Syringes
9.3.2. Vials
9.4. Oral
9.4.1. Capsule
9.4.2. Powder
9.4.3. Tablet
9.5. Topical
9.5.1. Cream
9.5.2. Gel
9.5.3. Patch
10. Drug Formulation Market, by Therapeutic Area
10.1. Introduction
10.2. Cardiovascular
10.2.1. Arrhythmia
10.2.2. Heart Failure
10.2.3. Hypertension
10.3. Infectious Diseases
10.3.1. Bacterial Infections
10.3.2. Parasitic Infections
10.3.3. Viral Infections
10.4. Neurology
10.4.1. Alzheimer's Disease
10.4.2. Multiple Sclerosis
10.4.3. Parkinson's Disease
10.5. Oncology
10.5.1. Hematological Malignancies
10.5.2. Solid Tumors
11. Drug Formulation Market, by Formulation Technology
11.1. Introduction
11.2. Controlled Release
11.2.1. Extended Release
11.2.2. Sustained Release
11.3. Molecular Engineering
11.3.1. Monoclonal Antibodies
11.3.2. Peptide Mimetic
11.4. Nanotechnology
11.4.1. Nanoemulsions
11.4.2. Nanoparticles
12. Drug Formulation Market, by Production Technology
12.1. Introduction
12.2. Bioprocessing
12.2.1. Chromatography
12.2.2. Fermentation
12.3. Chemical Synthesis
12.3.1. Catalysis
12.3.2. Solid State Chemistry
13. Drug Formulation Market, by End-User
13.1. Introduction
13.2. Clinics
13.2.1. Family Clinics
13.2.2. Specialty Clinics
13.3. Home Care Settings
13.3.1. Home Infusion
13.3.2. Remote Monitoring
13.4. Hospitals
13.4.1. In-Patient
13.4.2. Out-Patient
14. Drug Formulation Market, by Market Trends and Innovations
14.1. Introduction
14.2. 3D Printed Drugs
14.2.1. Complex Structures
14.2.2. Rapid Dissolution
14.3. Biosimilars
14.3.1. Interchangeable
14.3.2. Non-Interchangeable
14.4. Green Chemistry
14.4.1. Biodegradable Polymers
14.4.2. Microalgal Derivatives
14.5. Personalized Medicine
14.5.1. Genomics
14.5.2. Proteomics
15. Americas Drug Formulation Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Drug Formulation Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Drug Formulation Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. 3M Company
18.3.2. AbbVie Inc.
18.3.3. Amgen, Inc.
18.3.4. AstraZeneca plc.
18.3.5. Bayer AG
18.3.6. Boehringer Ingelheim International GmbH
18.3.7. Boston Scientific Corporation
18.3.8. Catalent, Inc.
18.3.9. Eli Lilly and Company
18.3.10. F. Hoffmann-La Roche AG
18.3.11. Gerresheimer AG
18.3.12. Gilead Sciences, Inc.
18.3.13. GlaxoSmithKline plc
18.3.14. Glenmark Pharmaceuticals Limited
18.3.15. Halozyme Therapeutics, Inc.
18.3.16. Johnson & Johnson Services, Inc.
18.3.17. Marksans Pharma Ltd.
18.3.18. Medicef Pharma
18.3.19. Merck & Co., Inc.
18.3.20. Novartis AG
18.3.21. Pfizer Inc.
18.3.22. Sanofi SA
18.3.23. Teva Pharmaceuticals Industries Ltd.
18.3.24. The Bristol-Myers Squibb Company
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. DRUG FORMULATION MARKET MULTI-CURRENCY
FIGURE 2. DRUG FORMULATION MARKET MULTI-LANGUAGE
FIGURE 3. DRUG FORMULATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUG FORMULATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY BLOOD PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOPHARMACEUTICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY HIGH-POTENCY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORPHAN DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUG FORMULATION MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUG FORMULATION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUG FORMULATION MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUG FORMULATION MARKET SIZE, BY GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUG FORMULATION MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUG FORMULATION MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUG FORMULATION MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUG FORMULATION MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUG FORMULATION MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DRUG FORMULATION MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DRUG FORMULATION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DRUG FORMULATION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DRUG FORMULATION MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DRUG FORMULATION MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DRUG FORMULATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DRUG FORMULATION MARKET SIZE, BY PEPTIDE MIMETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL DRUG FORMULATION MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL DRUG FORMULATION MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL DRUG FORMULATION MARKET SIZE, BY CATALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID STATE CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL DRUG FORMULATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL DRUG FORMULATION MARKET SIZE, BY FAMILY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL DRUG FORMULATION MARKET SIZE, BY REMOTE MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL DRUG FORMULATION MARKET SIZE, BY IN-PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL DRUG FORMULATION MARKET SIZE, BY OUT-PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL DRUG FORMULATION MARKET SIZE, BY COMPLEX STRUCTURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL DRUG FORMULATION MARKET SIZE, BY RAPID DISSOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL DRUG FORMULATION MARKET SIZE, BY INTERCHANGEABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL DRUG FORMULATION MARKET SIZE, BY NON-INTERCHANGEABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 104. GLOBAL DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 105. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 106. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROALGAL DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 107. GLOBAL DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 108. GLOBAL DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 109. GLOBAL DRUG FORMULATION MARKET SIZE, BY GENOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 110. GLOBAL DRUG FORMULATION MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 111. GLOBAL DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 129. AMERICAS DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. AMERICAS DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. AMERICAS DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 132. AMERICAS DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 133. AMERICAS DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. AMERICAS DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 135. AMERICAS DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 136. AMERICAS DRUG FORMULATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 137. AMERICAS DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 138. AMERICAS DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, 2018-2030 (USD MILLION)
TABLE 139. AMERICAS DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 140. AMERICAS DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 141. AMERICAS DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 142. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA DRUG FORMULATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL DRUG FORMULATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 203. CANADA DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 204. CANADA DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 205. CANADA DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 206. CANADA DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 207. CANADA DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 208. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 209. CANADA DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 210. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 211. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 212. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 213. CANADA DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 214. CANADA DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 215. CANADA DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 216. CANADA DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 217. CANADA DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 218. CANADA DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 219. CANADA DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 220. CANADA DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. CANADA DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. CANADA DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 223. CANADA DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 224. CANADA DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. CANADA DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 226. CANADA DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 227. CANADA DRUG FORMULATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 228. CANADA DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 229. CANADA DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, 2018-2030 (USD MILLION)
TABLE 230. CANADA DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 231. CANADA DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 232. CANADA DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 233. MEXICO DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 234. MEXICO DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 235. MEXICO DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 236. MEXICO DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 237. MEXICO DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 238. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 239. MEXICO DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 240. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 241. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 242. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 243. MEXICO DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 244. MEXICO DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 245. MEXICO DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 246. MEXICO DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 247. MEXICO DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. MEXICO DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 249. MEXICO DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 250. MEXICO DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. MEXICO DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 252. MEXICO DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 253. MEXICO DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 254. MEXICO DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. MEXICO DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 256. MEXICO DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 257. MEXICO DRUG FORMULATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 258. MEXICO DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 259. MEXICO DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, 2018-2030 (USD MILLION)
TABLE 260. MEXICO DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 261. MEXICO DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 262. MEXICO DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 263. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 264. UNITED STATES DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 265. UNITED STATES DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 266. UNITED STATES DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 267. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 268. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 269. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 270. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 271. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 272. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 273. UNITED STATES DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 274. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 275. UNITED STATES DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 276. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 277. UNITED STATES DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 278. UNITED STATES DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 279. UNITED STATES DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 280. UNITED STATES DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. UNITED STATES DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 283. UNITED STATES DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 284. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. UNITED STATES DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 286. UNITED STATES DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 287. UNITED STATES DRUG FORMULATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. UNITED STATES DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 289. UNITED STATES DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, 2018-2030 (USD MILLION)
TABLE 290. UNITED STATES DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 291. UNITED STATES DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 292. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 293. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 309. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 310. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 311. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 313. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 314. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 315. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 317. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 318. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 319. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY MARKET TRENDS AND INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 320. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY 3D PRINTED DRUGS, 2018-2030 (USD MILLION)
TABLE 321. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 322. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY GREEN CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 323. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 324. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 325. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 326. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 327. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 328. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY SPECIALTY DRUGS, 2018-2030 (USD MILLION)
TABLE 329. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY FORMULATION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, 2018-2030 (USD MILLION)
TABLE 341. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY MOLECULAR ENGINEERING, 2018-2030 (USD MILLION)
TABLE 342. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 343. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 344. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY BIOPROCESSING, 2018-2030 (USD MILLION)
TABLE 345. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 346. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 347. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 348. AUST

Companies Mentioned

  • 3M Company
  • AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca plc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Catalent, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gerresheimer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Marksans Pharma Ltd.
  • Medicef Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd.
  • The Bristol-Myers Squibb Company

Methodology

Loading
LOADING...

Related Topics

Related Reports

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), Drug Type (Over-The-Counter Drugs, Prescription Drugs), Route Of Administration, Drug Formulation, End-User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), Drug Type (Over-The-Counter Drugs, Prescription Drugs), Route Of Administration, Drug Formulation, End-User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Bioavailability Enhancement Technologies & Services Market - Global Forecast to 2030 - Product Image

Bioavailability Enhancement Technologies & Services Market - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Drug Formulation Market Report 2025 - Product Image

Drug Formulation Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 80 Pages
  • Global
From
A Journal of Drug Formulation, Development and Production - Product Image

A Journal of Drug Formulation, Development and Production

  • Journal Icon Journal
  • 60 Pages
  • Global
From

About the Drug Formulation Market

The Drug Formulation market is a key component of the Drug Discovery process. It involves the development of a drug product that is suitable for administration to a patient. This includes the selection of the appropriate drug delivery system, the optimization of the drug's physical and chemical properties, and the development of a manufacturing process. The formulation of a drug is a complex process that requires expertise in a variety of disciplines, including chemistry, pharmacology, and engineering. The Drug Formulation market is highly competitive, with a number of companies offering a range of services. These include formulation development, analytical testing, and manufacturing. Companies in the market include Pfizer, Merck, Novartis, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.